Overview

Clinical Trial of Dipyridamole in Schizophrenia

Status:
Completed

Trial end date:
2011-09-01

Target enrollment:
0

Participant gender:
All

Summary

This is a 6-week, randomized, double blind, parallel groups designed, olanzapine-controlled trial of oral dipyridamole in symptomatic patients with a (DSM IV) diagnosis of schizophrenia, schizoaffective or schizophreniform disorder. This pilot study aims to provide preliminary estimates of whether the effect sizes of dipyridamole on positive symptoms, negative symptoms, and cognitive deficits differ between schizophrenia patients treated with dipyridamole, and schizophrenia patients treated with olanzapine. A total of 30 subjects will be recruited locally.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

University of Maryland
University of Maryland, Baltimore

Treatments:

Dipyridamole
Olanzapine

Criteria

Inclusion Criteria:

- Subjects between ages 18-65, both males and nonpregnant females (on birth control)
Diagnosis of schizophrenia, schizoaffective or schizophreniform disorder Ability to
give written informed consent Total BPRS score > 27 Psychosis subscale scores > 7

Exclusion Criteria:

- Patients with coagulative disorders, bleeding diathesis or currently on
anticoagulants, and patients with major medical illnesses (including hypertension,
angina, and cardiovascular diseases) or an abnormal baseline ECG.

Patients with moderate to severe mental retardation.

Inability to sign informed consent.

Patients with a history of serious violence (e.g., suicide attempts, or assaultive
behavior).

Patients on clozapine treatment within the 6 weeks leading to the double-blind phase.

Patients with a history of olanzapine non-response

Positive Urine Toxicology Screen